title: Mucosal concentration of basic fibroblast growth factor in the healing process in human giant gastric ulcers.
abstract: OBJECTIVE
  Basic fibroblast growth factor (bFGF) is a key factor in the healing of human and experimental peptic ulcers, but the behavior of bFGF in human giant gastric ulcer remains to be determined. We determined the bFGF content in the rim of giant ulcers (bFGF rim) and in non-ulcerated mucosa located opposite the ulcer (bFGF opposite) before and during treatment.
  
  
  METHODS
  Biopsy specimens were endoscopically obtained from 31 patients with giant gastric ulcers and 17 patients with small ulcers before and 2, 4 and 8 weeks after treatment. The bFGF concentrations in the specimens were measured using a sandwich enzyme immunoassay.
  
  
  RESULTS
  Before treatment, the bFGF rim and bFGF opposite concentrations were not associated with ulcer size. The bFGF rim concentration before treatment in the rapid healing group was higher than that in the slow healing group, but no significant difference in bFGF opposite concentrations were found between the two groups. The bFGF rim concentration in the rapid healing patients decreased during treatment, while the slow healing patients showed an inverse response. The bFGF opposite concentration did not change during treatment and bFGF rim concentrations in Helicobacter pylori-positive stomachs were significantly lower than those in H. pylori-negative stomachs.
  
  
  CONCLUSIONS
  The bFGF rim concentration is not involved in the formation of giant gastric ulcers in humans. However, the bFGF rim concentration does appear to promote healing. The bFGF opposite concentration is not related to either the formation or healing of giant gastric ulcers.
authors.affiliation: Department of Internal Medicine, Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo 108-0073, Japan. amizuki@saichu.jp
authors.forename: Akira
authors.initials: A
authors.lastname: Mizuki
authors.forename: Masayuki
authors.initials: M
authors.lastname: Tatemichi
authors.forename: Hiromi
authors.initials: H
authors.lastname: Nishiya
authors.forename: Kazuto
authors.initials: K
authors.lastname: Fukui
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Hayashi
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Tsukada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nagata
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Ishii
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D001706:Biopsy; D005260:Female; D005346:Fibroblast Growth Factors / Q000378:metabolism*; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism / Q000473:pathology; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000175:diagnosis; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology; D013276:Stomach Ulcer / Q000378:metabolism* / Q000473:pathology; D013997:Time Factors; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D005346:Fibroblast Growth Factors; D009853:Omeprazole